Nicox SA (NICXF.PK), a French ophthalmic company, Monday announced that it has held a positive pre-New Drug Application or NDA meeting with the United States Food and Drug Administration or FDA regarding AC-170.
The purpose of the meeting was to discuss the clinical package for AC-170. Based on the available efficacy and safety data, the Agency recommended submission of the NDA.
AC-170 is a topical ocular formulation of cetirizine developed for the treatment of ocular itching associated with allergic conjunctivitis.
Nicox will hold an additional pre-NDA meeting regarding the Chemistry, Manufacturing and Controls or CMC data package, which is expected to take place in the first quarter of 2015. Nicox will update the market in due course on the expected NDA submission date.
AC-170 is a novel formulation of cetirizine being developed for the first time for topical application in the eye. Cetirizine is a second-generation histamine H1-receptor antagonist and a leading antihistamine.
AC-170 has been developed for the treatment of ocular itching associated with allergic conjunctivitis by Aciex Therapeutics, Inc., which became a wholly-owned subsidiary of Nicox in October 2014.
For comments and feedback contact: editorial@rttnews.com